Although K-RAS-induced lung cancer development can proceed via multiple pathways, the high frequency of RUNX3 inactivation in K-RAS-induced mouse and human lung ADCs suggests that a major pathway involves R-point disruption by RUNX3 inactivation prior to K-RAS activation. The gene discussed is KRAS; the disease is lung carcinoma.